全球瞩目的2026年欧洲肿瘤内科学会年会（ESMO Congress 2026）将于当地时间10月23日至27日在西班牙马德里盛大召开。7月17日，ESMO官网已公布了除LBA之外的常规摘要标题及讲者信息。【肿瘤资讯】特此整理了消化道肿瘤领域入选Proffered Paper Session与Rapid Oral Session的重磅临床研究，带您一睹前沿风采。
优选口头报告（Proffered Paper Session）
3530O - Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (LARC): The phase 3 UNION trial
中文标题：局部晚期直肠癌（LARC）新辅助短程放疗后序贯卡瑞利珠单抗和化疗：UNION III期试验
讲者：张涛 华中科技大学同济医学院附属协和医院
2875O - Pembrolizumab or placebo plus concurrent definitive chemoradiotherapy in esophageal and gastroesophageal junction (GEJ) cancer: the Phase 3 randomized KEYNOTE-975 study
中文标题：帕博利珠单抗或安慰剂联合同步根治性放化疗治疗食管癌和胃食管结合部（GEJ）癌：KEYNOTE-975 III期随机研究
讲者：Manish A. Shah (New York, United States of America)
459O - A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer
中文标题：紫杉醇±Tovecimig治疗既往经治的晚期胆道癌患者的随机试验
讲者：Nilofer S. Azad (Baltimore, United States of America)
快速口头报告（Rapid Oral session）
上消化道肿瘤
2876RO - TQB2102, a Novel HER2 Bispecific Antibody-Drug Conjugate, Combined with Bemotrizumab with or without Capecitabine as First-Line Therapy for HER2-Positive Advanced Gastric/Gastroesophageal Junction Cancer: A Phase II Study
中文标题：TQB2102，一种新型HER2双特异性抗体药物偶联物，联合Bemotrizumab伴或不伴卡培他滨作为HER2阳性晚期胃/胃食管交界部癌一线治疗：一项II期研究
讲者：徐瑞华 中山大学肿瘤防治中心
2877RO - Watch-and-wait (W&W) strategy for dostarlimab in localized deficient dMMR/MSI-H gastroesophageal adenocarcinoma (GEA): Results from the first interim analysis of the GERCOR-GONO DEWI phase II study
中文标题：局部缺陷型dMMR/MSI-H胃食管腺癌（GEA）中Dostarlimab的观察&等待策略（W&W）：GERCOR-GONO DEWI II期研究首次中期分析结果
讲者：Thierry André (Paris, France, CEDEX 12)
2878RO - FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study
中文标题：FOLFIRI联合雷莫西尤单抗对比紫杉醇联合雷莫西尤单抗作为紫杉类经治的晚期或转移性胃食管腺癌患者二线治疗——IKFs602/AIO RAMIRIS III期研究最终结果
讲者：Sylvie Lorenzen (Munich, Germany)
2879RO - Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma : ARION PRODIGE 67 randomized phase 2 trial
中文标题：度伐利尤单抗联合同步根治性放化疗对比单纯同步根治性放化疗治疗局部晚期食管癌患者：ARION PRODIGE 67随机II期试验
讲者：Marie-Anouchka Modesto (Toulouse, France)
3136RO - Randomised Phase II study of mFOLFIRINOX±SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial
中文标题：mFOLFIRINOX方案±SBRT治疗高危、临界可切除或局部晚期胰腺癌患者的随机II期研究：AGITG MASTERPLAN试验结果
讲者：Andrew Oar (Southport, Australia)
3137RO - Safety and Efficacy of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Combination with Chemotherapy in Patients (pts) with Advanced/Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
中文标题：INCB161734，一种新型口服KRAS G12D抑制剂，联合化疗用于晚期/转移性胰腺导管腺癌（PDAC）患者的安全性和有效性
讲者：Antoine Hollebecque (Villejuif, France)
1678RO - Phase 3 LEAP-012 Study of Lenvatinib + Pembrolizumab vs Dual Placebo With Transarterial Chemoembolization (TACE) for Unresectable Non-metastatic Hepatocellular Carcinoma: Long-term OS Results
中文标题：仑伐替尼+帕博利珠单抗对比安慰剂联合经动脉化疗栓塞（TACE）用于不可切除非转移性肝细胞癌的LEAP-012 III期研究：长期OS结果
讲者：Josep M. Llovet (Barcelona, Spain)
1679RO - Phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) Monotherapy: First Disclosure of Dose Optimization (DO) and Dose Escalation (DE) Update in Advanced Hepatocellular Carcinoma (HCC)
中文标题：BGB-B2033（GPC3 × 4-1BB双特异性抗体）单药治疗的I期研究：晚期肝细胞癌（HCC）中剂量优化（DO）和剂量递增（DE）更新的首次披露
讲者：Hong Jae Chon (Seongnam, Republic of Korea)
1680RO - Phase I study of C-CAR031, a GPC3-targeted TGFβRIIDN armored autologous CAR-T, in advanced hepatocellular carcinoma (aHCC): Updated Results
中文标题：C-CAR031，一种靶向GPC3的TGFβ RIIDN装甲型自体CAR-T治疗晚期肝细胞癌的 I 期研究更新结果
讲者：梁廷波 浙江大学医学院附属第一医院
快速口头报告（Rapid Oral session）
下消化道肿瘤
787RO - Circulating tumor DNA (ctDNA)-guided re-treatment (re-tx) with encorafenib and cetuximab (EC) in patients (pts) with chemorefractory BRAFV600E mutated metastatic colorectal cancer (mCRC): the proof-of-concept single arm phase II BRICKET trial by GONO
中文标题：循环肿瘤DNA（ctDNA）指导下的恩考芬尼联合西妥昔单抗（EC）再治疗用于化疗难治性BRAFV600E突变转移性结直肠癌（mCRC）患者：GONO开展的BRICKET概念验证性单臂II期试验
讲者：Marco Maria Germani (Pisa, Italy)
788RO - Encorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: results from the ECLYPse phase II trial
中文标题：恩考芬尼联合西妥昔单抗（EC）进展后联用FOLFIRI用于EC治疗后进展的BRAF V600E突变转移性结直肠癌（mCRC）患者：ECLYPse II期试验结果
讲者：Maria Alessandra Calegari (Rome, Italy)
789RO - TRIDENTE: A phase II study of rechallenge with encorafenib (ENCO), binimetinib (BINI), and cetuximab (CET) in BRAF V600E-mutant metastatic colorectal cancer (mCRC)
中文标题：TRIDENTE：恩考芬尼（ENCO）、比美替尼（BINI）和西妥昔单抗（CET）再挑战用于BRAF V600E突变转移性结直肠癌（mCRC）的II期研究
讲者：Daisuke Kotani (Kashiwa, Japan)
790RO - Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor, in combination with cetuximab ± mFOLFOX6 in patients with KRASG12D-mutated colorectal cancer (CRC)
中文标题：QTX3034，一种口服G12D偏好活性KRAS抑制剂，联合西妥昔单抗±mFOLFOX6用于KRASG12D突变结直肠癌（CRC）患者的初步临床结果
讲者：Ignacio Garrido-Laguna (Salt Lake City, United States of America)
791RO - Long-term follow-up of Telisotuzumab Adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study
中文标题：Telisotuzumab Adizutecan（ABBV-400，Temab-A）联合贝伐珠单抗（Bev）对比标准治疗（SOC）用于3L+结直肠癌（CRC）患者的长期随访：一项I期研究更新结果
讲者：Michael Cecchini (New Haven, United States of America)
排版编辑：肿瘤资讯-QTT
苏公网安备32059002004080号
